A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Washington University School of Medicine
H. Lee Moffitt Cancer Center and Research Institute
Barbara Ann Karmanos Cancer Institute
University of Liverpool
Alliance for Clinical Trials in Oncology
Universitätsklinikum Hamburg-Eppendorf
Columbia University
University of Nebraska
Huashan Hospital
OHSU Knight Cancer Institute
Trans Tasman Radiation Oncology Group
M.D. Anderson Cancer Center
University of California, Davis
Gruppo Italiano Malattie EMatologiche dell'Adulto
H. Lee Moffitt Cancer Center and Research Institute
UNICANCER
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
OHSU Knight Cancer Institute
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Royal Marsden NHS Foundation Trust
University of Arizona
M.D. Anderson Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
M.D. Anderson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Asan Medical Center
Stanford University
Royal Marsden NHS Foundation Trust
Stanford University
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
Newcastle-upon-Tyne Hospitals NHS Trust
French Innovative Leukemia Organisation
Memorial Sloan Kettering Cancer Center
Vanderbilt-Ingram Cancer Center
Istituto Clinico Humanitas
Memorial Sloan Kettering Cancer Center